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Background: Staphylococcus aureus is unrestrictedly found in humans and in animal species that maintain thermal
homeostasis. Inadequate cleaning of processing equipment or inappropriate handling can contaminate processed
food and cause severe food poisoning. Staphylococcal enterotoxin B (SEB), a potent superantigenic exotoxin, is
produced by 50% of clinical isolates of S. aureus and is associated with massive food poisoning and with the
induction of toxic shock syndrome.
Results: A gene sequence encoding a recombinant SEB (rSEB), devoid of superantigenic activity, was successfully
cloned and expressed in a cytoplasmic or a secreted form in the food-grade lactic acid bacterium Lactococcus lactis.
The recombinant protein detected in the cytoplasm or in the culture medium exhibited the expected molecular
mass and was recognized by a SEB-polyclonal antibody. Oral immunization with the recombinant L. lactis strains
induced a protective immune response in a murine model of S. aureus infection. Immunized mice survived
intraperitoneal challenge with an S. aureus SEB-producer strain. Counts of S. aureus in the spleen of rSEB-immunized
mice were significantly reduced. The rSEB-immunized mice showed significant titers of anti-SEB IgA and IgG in
stools and serum, respectively. Both recombinant L. lactis strains were able to elicit cellular or systemic immune
responses in mice, with no significant difference if rSEB was produced in its cytoplasmic or secreted form. However,
recombinant L. lactis expressing the cytoplasmic rSEB increased the survival rate of the challenged mice by 43%.
Conclusions: These findings show the vaccine efficacy of L. lactis carrying an attenuated SEB, in a murine model,
following lethal S. aureus challenge.
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Staphylococcus aureus is a Gram-positive opportunistic
pathogen of humans and warm-blooded animals, and is
part of the commensal microbiota of the skin and nares in
a significant proportion of the human population. It is a
leading cause of bloodstream, lower respiratory tract, and
skin and soft-tissue infections. Moreover, S. aureus has a
wide range of virulence factors, including superantigens
such as staphylococcal enterotoxins (SEs). These heat-
stable toxins cause a self-limiting gastrointestinal intoxica-
tion, but parenteral exposures can cause a potentially fatal
toxic shock syndrome [1-3]. Staphylococcal enterotoxin
type B (SEB) is a single polypeptide of approximately
27 kDa, highly resistant to proteases [4]. As a superantigen,
SEB is capable of massive activation of CD4+ lymphocytes,
with subsequent secretion of cytokines and systemic in-
flammation [5]. Because of its remarkable toxicity and sta-
bility, SEB is considered a prime threat as a biological
weapon of mass destruction [6-8]. Bacterial superantigens
can be inactivated by rational site-directed mutagenesis,
and these genetically altered constructs can be used for
vaccine purposes [9,10]. Additionally, various vaccination
regimens of an attenuated SEB mutant protein containing
L45R, Y89A and Y94A were effective in a primate model
against aerosolized wild-type SEB, with a correlation be-
tween survival of rhesus monkeys, antibody titers, and neu-
tralizing antibody [11].
Lactic acid bacteria (LAB) have been considered good
candidates for controlled and targeted administration of
heterologous proteins to the mucosal immune system
[12,13]. Lactococcus lactis is widely used as a starter in
the dairy industry and is considered a model organism
for LAB. Several genetic tools for the model LAB,
Lactococcus lactis, were developed: transformation pro-
tocols, cloning- or screening-vectors and mutagenesis
[14] (for a review) and the complete genome sequence is
now available for several strains [15]. L. lactis has been
extensively used for antigen delivery [12,16-18] thanks
to genetic tools allowing antigen production in different
cellular compartments (intracellular, secreted, or anchored
to the cell wall) [8,19]. L. lactis has also been used to effi-
ciently produce, secrete, and deliver therapeutic proteins
to the mucosal tissues, specifically through the intranasal,
oral, or genital mucosal surfaces [12,17]. Sufficient data
are now available to support the use of recombinant LAB,
in particular L. lactis, to deliver therapeutic proteins to the
mucosal tissues [8,20]. Mucosal vaccination is able to
stimulate an immune response at the site of invasion, pro-
viding a first line of defense against pathogens [13,21]. In
addition, oral immunization frequently evokes both local
and systemic immune responses, resulting in the effective
elimination of foreign invaders [13].
The objective of this study was to explore the efficacy
of an oral vaccine in C57Bl/6 mice, using L. lactis strainsto deliver a recombinant SEB protein lacking super-
antigenic activity [10]. This rSEB variant was obtained
after mutations in a hydrophobic binding loop, polar
binding pocket, and disulfide loop (L45R, Y89A, and
Y94A, respectively) without affecting the antigenic char-
acteristics of SEB [10,11]. The humoral immune re-
sponse against rSEB in mice was characterized, and its
protective effect was evaluated through a challenge in-
fection using a live SEB-producer strain of S. aureus.
Results
Engineering of recombinant L. lactis strains producing
cytoplasmic and secreted forms of rSEB
Since the immune response to an antigen depends on its
presentation [12] we engineered L. lactis for the intracel-
lular delivery of rSEB or secretion of rSEB by L. lactis
to the intestinal mucosa. Two expression vectors were
initially constructed, pCYT:rSEB and pSEC:rSEB for the
cytoplasmic expression or secretion of rSEB, respectively
(see Methods for details). The pCYT:rSEB vector har-
bors a transcriptional fusion between the ribosome-
binding site (RBSusp45) of the usp45 gene [22] and the
DNA sequence encoding the mature moiety of rSEB,
and the pSEC:rSEB harbors a transcriptional fusion be-
tween RBSusp45 and the DNA sequence encoding the
signal peptide (SPusp45) of Usp45 plus rSEB. In both
cases, rSEB expression was under the control of the
xylose-inducible promoter, PxylT [14]. The ability of
L. lactis to secrete rSEB or to accumulate rSEB intracel-
lularly was examined using L. lactis (pSEC:rSEB) and
L. lactis (pCYT:rSEB), respectively, after induction with
1% xylose. Cell pellet and supernatant protein samples
from L. lactis carrying pCYT:rSEB or pSEC:rSEB, re-
spectively, were prepared from late exponential-phase
cultures (cells harvested at OD600 1.5), resolved by SDS-
PAGE and transferred onto a PVDF membrane. Produc-
tion of rSEB, in the culture medium or in the whole-cell
extracts, was analyzed by Western blotting, using a com-
mercial polyclonal anti-staphylococcal enterotoxin B
antibody (anti-SEB) as a probe. A single band with the
expected size for rSEB (27 kDa) – available in the Pro-
tein families database Pfam [http://www.sanger.ac.uk/
Software/Pfam/search.shtml] - was identified in the cell
pellet (Figure 1, lane 2) and in culture supernatants
(Figure 1, lane 4) of induced L. lactis (pCYT:rSEB) and
L. lactis (pSEC:rSEB), respectively. The 27 kDa poly-
peptide band was not detected in the samples prepared
from non-induced recombinant L. lactis (Figure 1, lanes
3 and 5). Protein extracts of S. aureus ATCC 14458 (an
SEB producer) and of a non-SEB producer S. aureus (strain
from our laboratory collection) were used as positive
(Figure 1, lanes 6, 7 and 8) and negative (Figure 1, lane 9)
controls, respectively. Taken together, the results showed
that L. lactis carrying (pCYT:rSEB) or (pSEC:rSEB) was
pCYT:rSEB   pSEC:rSEB         S. aureus
+xyl   –xyl    +xyl   –xyl          +SEB          -SEB
27 kDa
1    2        3       4       5       6     7     8      9
Figure 1 Expression of rSEB in Lactococcus lactis pSEC:rSEB
(secreted) and pCYT:rSEB (cytoplasm) after induction by 1%
xylose, assayed in supernatants or cell pellets, respectively.
rSEB expression was analyzed by Western blot using a commercial
polyclonal anti-staphylococcal enterotoxin B antibody (anti-SEB), as a
probe. rSEB (27 kDa) is indicated by an arrow. Lane 1 – prestained
protein molecular weight markers (Fermentas); lanes 2 and 4, -
induced (+ xyl); lanes 3 and 5, non-induced (+ xyl) cultures; lanes 6,
7 and 8, cell pellets from S. aureus cultures + SEB (ATCC 14458 strain/
SEB producer strain); lane 9, – SEB (29 strain/SEB non-producer
strain). The arrow indicates the SEB of an apparent molecular mass
of 27 kDa.
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rSEB, both of which were properly recognized by the anti-
SEB antibody.
Protective effect of oral immunization with rSEB
To determine the efficacy of the recombinant L. lactis
strains as a live vaccine against S. aureus, mice were or-
ally immunized with 109 CFU of each strain expressing
rSEB, either in the cytoplasm or secreted in the intes-
tinal mucosa. The rSEB expression was induced in eachFirst 
Immunization
days  0, 1, 2
Boosting 1











Figure 2 Immunization, serum and stool collection, and challenge sch
model, four groups of 10 C57Bl/6 mice were tested, designated PBS, Lactoc
schedule. Each group was immunized orally on days 0/1/2, and boosted on
were bled three times, on days 14, 28 and 42. Stools were collected on day
Staphylococcus aureus ATCC 14458. The animals were killed at the end of thstrain prior to oral administration, as described in the
Methods section. Control groups were immunized with
wild-type L. lactis NCDO2118 or with PBS. Mice re-
ceived a booster immunization for three consecutive
days. Fourteen days after the last immunization, the
mice were challenged with a lethal dose of S. aureus
ATCC 14458, a SEB producer strain (7 × 108 CFU per
mouse), by intraperitoneal (i.p.) administration (Figure 2).
Fourteen days after the S. aureus challenge, 100% of the
mice vaccinated with L. lactis pCYT:rSEB and 70% of
those vaccinated with L. lactis pSEC:rSEB survived. In
contrast, only 10% of the mice injected with PBS or
L. lactis NCDO2118 (wt strain) survived the lethal chal-
lenge (Figure 3). Three days after inoculation, the num-
ber of bacterial cells in the spleens was determined.
The rSEB-immunized mice presented significantly fewer
S. aureus cells in the spleens compared to the control mice
(Figure 4). Bacterial counts were not significantly different
between the animals that were immunized with the cyto-
plasmic or the secreted form of rSEB (p < 0.01). There
was no significant difference in the counts of S. aureus in
the spleen of control mice that received PBS or L. lactis
NCDO 2118. These results indicate that each animal im-
munized with L. lactis pCYT:rSEB and L. lactis pSEC:rSEB
developed protection against systemic S. aureus ATCC
14458 infection.
In sum, oral immunization with rSEB delivered by L.
lactis appeared to provide efficient protection and pro-
moted survival against infection by a lethal S. aureus
SEB producer.
Production of anti-SEB antibody in orally immunized mice
The production of SEB-specific IgG in serum and IgA
antibody in feces was determined by specific ELISA
during the time course of the immunization (Figure 5).
Each animal responded with a strong, stable antibody re-
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Figure 3 Survival rates of immunized mice. 10 animals in each group previously immunized with Lactococcus lactis pCYT:rSEB, L. lactis pSEC:








































Figure 4 Enumeration of Staphylococcus aureus in the spleen of
immunized mice. 10 animals in each group were immunized with
Lactococcus lactis pCYT:rSEB, L. lactis pSEC:rSEB, L. lactis NCDO2118,
or PBS and then challenged with 7 × 108 CFU of S. aureus ATCC
14458 (SEB producer) on the 14th day after the last boost, as
described in the Methods section. Significant results are marked
with asterisks: *** p < 0.05.
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crease 42 days after the first immunization (Figure 5A).
Interestingly, immunization with L. lactis pSEC:rSEB
induced an anti-SEB antibody production, which was
stronger than that induced by L. lactis pCYT:rSEB, at
days 14 and 28. However, specific anti-SEB antibody ti-
ters reached the same levels at day 42, in both immuni-
zations. Fecal SEB-IgA antibodies increased significantly
after immunization with rSEB-producing L. lactis strains
with either the cytoplasmic or secreted form (Figure 5B).
It appears that the intracellular presentation of rSEB by
L. lactis or the presentation in a secreted form to the
mucosal site results in a similar stimulation of local IgA
antibodies.
The data presented here demonstrated that the oral
administration of recombinant L. lactis strains carrying
pSEC:rSEB or pCYT:rSEB stimulated both the serum-
SEB IgG and mucosal IgA specific antibodies in mice.
Discussion
Production of several staphylococcal proteins in L. lactis
has been reported. However, these studies were dedi-
cated to the development of expression-secretion sys-
tems, e.g., staphylococcal nuclease used as a reporter
protein [23]; to the characterization of staphylococcal
virulence factors (e.g., ClfA and FnbA [24], ClfB [25],
IsdA [26]); or to increase adhesion properties of recom-
binant L. lactis strains [27]. In addition, several staphylo-
coccal antigen candidates have been tested alone or in
combination for immunization in animal models [28,29].
Proteins such as ClfA [30], recombinant forms of SEB
[2] or SEC [31], as well as non-protein molecules such
as capsular polysaccharides [29,32,33] are the most
widely investigated S. aureus antigens. To our know-
ledge, this study reports, for the first time, the produc-
tion of a staphylococcal antigen in a recombinant LAB
strain to be used for oral vaccination. The two recom-
binant L. lactis strains constructed here allow for theproduction of a non-superantigenic rSEB, either intracel-
lularly or secreted in the intestinal mucosa of mice,
which stimulates the production of specific anti-SEB IgG
antibodies in the serum and specific IgA in feces [12,34].
There is an apparent discrepancy between survival and
anti-SEB IgG production when compared the CYT:rSEB
and SEC:rSEB groups. It should be considered that the
antigen presentation pathway (secreted versus intracellu-
lar) may also impact the quality of neutralizing anti-
bodies, the reason that these alternative forms were
tested. The immune response can reflect the production
of different classes of IgG or the production of IgGs
against rSEB epitopes with distinct neutralizing abilities
Oral immunization with the recombinant strains in-
duced a protective immune response against a lethal














































































Figure 5 Specific SEB antibodies. Sera (A) and stools (B) from the
different groups of mice were collected and analyzed by ELISA after
the first oral administration. Immune response was assayed in mice
orally immunized with recombinant Lactococcus lactis pSEC:rSEB or
pCYT:rSEB. Significant results are marked with asterisks: *, p < 0.05;
** p < 0.01. Values were recorded as standard deviation of samples
from 10 mice per group.
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S. aureus ATCC 14458 exoproteome revealed that this
strain produces and secretes, in addition to SEB, other
enterotoxin-like proteins such as SElK and SElQ, together
with other toxins such as alpha-hemolysin and gamma-
hemolysin [35]. Thus, it seems that oral immunization
with a recombinant L. lactis producing rSEB confers a
protective immunity against a strain of Staphylococcus
that produces a variety of enterotoxins. Alternatively, one
might consider that SEB, as a potent superantigen, is
preponderant in the pathogenesis of SEB-producing
strains. TSST1 and SEB production was indeed shown
to repress exotoxin synthesis in S. aureus [36]. Similarly,
encouraging results were obtained using a recombinant
SEC mutant vaccine against mastitis. Intramuscular
immunization resulted in significant protection against
a challenge with live SEC-producer S. aureus strains in
dairy cows [31]. In addition to these SE-oriented vac-
cines, other immunization strategies against S. aureus
were developed, based on other staphylococcal antigens
that are widely distributed among S. aureus strains,such as adhesins [32], IsdB [28], ClfA or exopoly-
saccharides [30].
Previous studies reported a protective immunization
against lethal challenge with SEB after oral or nasal
immunization using SEBv, a non-superantigenic variant
of SEB. Significant protection was observed only when
cholera toxin was used as an adjuvant [26].
The effect of the vaccination route on immunogenicity
has to be considered. In a previous study, Stiles et al. [2]
showed that immunization via the nasal route yielded
higher titers of circulating IgG when compared to the
oral route. An intranasal immunization route yielded a
better immune response, compared to the oral route, in
a live-vaccine strategy using L. lactis producing the
HPV16 E7 antigen [12]. Whether nasal immunization
with our recombinant L. lactis strains would confer an
even better protection remains to be tested.
Conclusions
Lactococcus lactis, a food-grade organism that carries
and expresses an attenuated form of enterotoxin B
(rSEB) appears to be an efficient delivery vehicle for
immunization in mice against the toxic shock provoked
by Staphylococcus aureus. The live vaccine can be ad-
ministered orally and can be considered a promising tool




Six- to eight-week-old C57Bl/6 mice were purchased
from Cecal, Fiocruz, Rio de Janeiro, Brazil. Mice were
housed in plastic cages under specific pathogen-free
conditions at the Department of Immunology, UFRJ.
The daily cycle consisted of 12 h light and 12 h dark-
ness, and food and water were available at all times. The
experiments were approved by the Institutional Animal
Welfare Committee (approval ID: CEUA/CCS/UFRJ/
IMPPG 011).
Bacterial strains, growth conditions and plasmids
Escherichia coli TG1 was aerobically grown at 37°C in
Luria-Bertani medium. L. lactis NCDO2118 was grown
anaerobically at 30°C in M17 medium supplemented with
0.5% glucose. When required, antibiotics were added as
follows: ampicillin (100 μg/mL) for E. coli and chloram-
phenicol (10 μg/mL) for L. lactis. rSEB was cloned into
lactococcal plasmids pCYT:Nuc and pSEC:Nuc under the
regulation of a xylose-inducible promoter, PxylT [17].
rSEB was produced either in the cytoplasm (CYT) or into
the extracellular medium (SEC). For the sake of simplicity,
these constructions are hereafter referred to as pCYT:
rSEB, and pSEC:rSEB, referring to the location of the re-
combinant protein.
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General DNA manipulation techniques were carried out
according to standard procedures [37]. DNA restriction
and modification enzymes were used as recommended
by the suppliers. DNA fragments were isolated from agar-
ose gels with the Concert™ Rapid Gel Extraction System
(Gibco BRL). PCR amplifications were performed using
Taq DNA polymerase (Invitrogen) in a DNA thermocycler
(MJ Research, Inc.). DNA plasmids from E. coli and L.
lactis were isolated as previously described [37,38].
The vectors to produce cytoplasmic or secreted rSEB,
pCYT:rSEB, and pSEC:rSEB, respectively, were obtained
as follows: A 721-bp DNA fragment encoding rSEB was
PCR-amplified from a plasmid previously described [10]
and subcloned into pGEM-T (Promega) cloning vector,
resulting in pGEM:rSEB. A primer pair was then
designed based on rSEB sequence: 5'GGCTGCAG
AGAGTCAACCAGATCCT-3' for the coding strand
containing a PstI restriction site (underlined) and 5'G
GGAATTCTCACTTTTTCTTTGTCGT-3' for the com-
plementary strand, containing an EcoRI restriction site
(underlined). The rSEB fragment resulting from PstI and
EcoRI digestion of pGEM:rSEB was cloned into a NsiI-
EcoRI-cut and the purified backbone of the pCYT:Nuc
expression vector, replacing the DNA sequence encoding
NucB. The pSEC:rSEB vector was constructed to target
the rSEB protein to the extracellular medium (i.e., se-
creted) of L. lactis, using the following procedures: the
rSEB gene was PCR-amplified from pGEM:rSEB using
5'GGCTGCAGAGAGTCAACCAGATCCT-3' (including
a PstI site; underlined) as forward primer and 5'GG
GAATTCTCACTTTTTCTTTGTCGT-3' (including an
EcoRI site; underlined) as reverse primer. The PCR prod-
uct was then PstI- and EcoRI-digested and cloned, in
frame with the signal peptide coding sequence, into the
purified backbone isolated from the NsiI-EcoRI-cut
pSEC:Nuc expression vector, again replacing the DNA
sequence encoding for NucB. In both cases, pCYT:rSEB
and pSEC:rSEB were first obtained in E. coli TG1 and
then transferred into L. lactis NCDO2118. All construc-
tions were confirmed by DNA sequencing.
Conditions of xylose induction
L. lactis strains harboring pCYT:rSEB or pSEC:rSEB
were grown at 30°C overnight in 10 mL M17, containing
0.5% glucose. For xylose induction, 1 μL of the culture
was transferred into 10 mL M17 medium supplemented
with 1% xylose in the presence of chloramphenicol
(10 ng/mL) [14].
Protein sample preparation and Western blotting analysis
Protein samples from L. lactis cultures were prepared as
previously described [39], except for the use of protease
inhibitors and mild protein precipitation procedures.Briefly, protein extracts were prepared from 2 mL of
cultures centrifuged at 17,500 × g at 4°C for 10 min.
The cell pellet and supernatant were treated separately.
To inhibit proteolysis in supernatant samples, 1 mM
phenylmethylsulfonyl fluoride (PMSF) and 10 mM
dithiothreitol (DTT) were added. Proteins were then pre-
cipitated by addition of 100 μL of 100% trichloroacetic
acid. The supernatant proteins were incubated for 1 h on
ice, and collected by centrifugation (17,500 × g at 4°C for
20 min). Supernatant proteins were resuspended in
50 mM NaOH, 1 mM PMSF, and 1.2 μL DTT-LB (4 mL
charge buffer solution, consisting of 0.1 Tris–HCl pH 6.8,
4% SDS, 10 ml glycerol, 0.2% bromophenol blue, 50 mL
distilled water q.s.p., and 1 mL of 1 M DTT). The cell pel-
lets were resuspended in 120 μL of TES-Lys buffer (25%
sucrose, 1 mM EDTA, 50 mM Tris–HCl pH 8.0 and
1 mg/mL of lysozyme), 1.2 μL DTT and 1 mM PMSF. The
suspension was incubated for 30 min at 37°C, and 20%
SDS, 1.2 μL DTT-LB and 1 mM PMSF were added. Super-
natant or pellet proteins were separated in a 12% PAGE-
SDS [40]. The gel-resolved proteins were transferred onto
a PVDF membrane and probed with a commercial poly-
clonal anti-staphylococcal enterotoxin B antibody (anti-
SEB, Sigma-Aldrich). Immunodetection was carried out
using peroxidase conjugates (Sigma-Aldrich).
Immunization and antibody detection
The animal study was conducted according to current
Good Scientific Practice-principles (2000) and approved
by the Ethical Committee of the UFRJ. Groups of C57Bl/6
mice (8–10 mice per group) were orally immunized with
109 CFU of each recombinant strain suspended in 100 μL
of sterile PBS for 3 consecutive days. The immunization
protocol was repeated twice at 2-week intervals. Control
groups received sterile PBS or a plasmidless L. lactis
NCDO2118, in the same conditions. Blood samples were
drawn on days 0, 14, 28 and 42 after immunization. Serum
samples were examined by ELISA for IgG titers with
specific antigen-binding activity after coating 1 μg/mL
SEB in carbonate buffer (S4881 - Sigma-Aldrich) onto
microplates. Anti-Mouse IgG Peroxidase antibody
(Sigma-Aldrich) diluted 1:1000 was used as the second-
ary antibody. Stool samples were obtained 0, 15, 24, and
38 days after immunization and were examined by
ELISA for IgA titers with specific antigen-binding activ-
ity after coating the microplate in the same way as for
IgG ELISA. The secondary antibody, Anti-Mouse IgA
Peroxidase antibody (A4789, Sigma-Aldrich) was di-
luted 1:1000.
Inoculum for lethal challenge
S. aureus ATCC 14458, an SEB-producer strain, was first
grown on BHI agar (Difco) for 18 h. Freshly grown col-
onies were suspended in BHI broth (Difco) and incubated
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tion at 4000 × g for 10 min at 4°C, and cell density was
adjusted to 7 × 108 CFU/mL. The inoculum size was con-
firmed by serial dilutions and quantitative subcultures on
Baird Parker agar, and the infecting dose was established
based on constructed lethality curves. The challenge dos-
age was established by a lethality assay, where the dosage
ranged from 109 CFU to 5 × 108 CFU of S. aureus
ATCC14458 administered to 6 animals with similar body
mass. The concentration of 7×108 CFU was able to kill ap-
proximately 70% of animals.Challenge tests
10 mice in each group (PBS, L. lactis, pSECrSEB, and
pCYTrSEB) were challenged 14 days after the last booster
with a lethal dose of S. aureus ATCC 14458 by intraperito-
neal (i.p.) injection. Untreated mice (control groups) were
infected in the same way. Mice were killed on the third
day after challenge (day 3) and the spleen was excised,
weighed, and homogenized in 1 mL sterile PBS. Homoge-
nates were analyzed by plating 10-fold serial dilutions, in
duplicate, on Baird Parker agar supplemented with egg
yolk tellurite emulsion. Colonies were counted after incu-
bation at 37°C for 18 h. Results were expressed as log of
CFU/g of spleen. Mouse deaths were recorded for 15 days.Statistical analysis
Data were analyzed by ANOVA, followed by Bonferroni’s
test to determine the significance of differences in anti-
body titers between the control and experimental groups.
A plot of the Kaplan-Meier method was used to estimate
the survival fractions, and significance was determined by
a log rank test. Differences in bacterial counts in the
spleen were evaluated by Student’s t test and Tukey’s mul-
tiple comparison test.
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